[CAS NO. 1219927-22-6] RO2959hydrochloride
PRODUCTS SPECIFICATIONS [1219927-22-6]
DESCRIPTION [1219927-22-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | C21H19F2N5OS.xHCl |
| SMILES | O=C(NC1=NC=C(C2=C(C)CCN(C3=NC=C(C)S3)C2)N=C1)C4=C(F)C=CC=C4F.[xHCl] |
Summary
RO2959 hydrochloride is a potent and selective CRAC channel inhibitor with an IC 50 of 402 nM. RO2959 hydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC 50 of 25 nM. RO2959 hydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways [1] [2] .
IC50 & Target
|
CRAC channel 402 nM (IC 50 ) |
Orai1/Stim1 channels 25 nM (IC 50 ) |
IL-2
|
In Vitro
RO2959 inhibits Orai1 and Orai3 with IC
50
values of 25 nM and 530 nM, respectively. RO2959 blocks store operated calcium entry (SOCE) in activated CD4+T lymphocytes with an IC
50
value of 265 nM
[1]
.
RO2959 is a potent SOCE inhibitor that blocks an IP3-dependent current in CRAC-expressing RBL-2H3 cells and CHO cells stably expressing human Orai1 and Stim1, as well as SOCE in human primary CD4
+
T cells triggered by either T cell receptor (TCR) stimulation or thapsigargin treatment. RO2959 completely inhibits cytokine production as well as T cell proliferation mediated by TCR stimulation or MLR (mixed lymphocyte reaction)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
References
- [1] Gang Chen, et al. Characterization of a Novel CRAC Inhibitor That Potently Blocks Human T Cell Activation and Effector Functions. Mol Immunol. 2013 Jul;54(3-4):355-67.
- [2] Changbo Zheng, et al. Gastrodin Inhibits Store-Operated Ca 2+ Entry and Alleviates Cardiac Hypertrophy. Front Pharmacol. 2017 Apr 25;8:222.